RxDoctor Payments Data

Jonathan Eckstein, DO

Family Medicine · Howard Beach, NYNPI 1346266699

Payments from drug & device makers

$794in general payments, 2019–2025

Across 37 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$192
  • Lilly USA, LLC$96
  • Novo Nordisk$93
  • Boehringer Ingelheim$74
  • Ascensia Diabetes Care US Inc.$60
  • AbbVie$52
  • plus $228 from 8 others

What the payments were for

  • Food & beverage$73592%
  • Education$608%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$794 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$204,719
Medicare patients
417
Services billed
2,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide45$84,270
JardianceEmpagliflozin56$71,695
MounjaroTirzepatide30$46,677
OzempicSemaglutide29$38,303
JanuviaSitagliptin Phosphate19$30,556
JanumetSitagliptin Phos/Metformin Hcl18$22,436
EliquisApixaban21$21,873
XareltoRivaroxaban17$21,407
TrulicityDulaglutide14$19,156
FarxigaDapagliflozin Propanediol16$16,986
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$8,644
Atorvastatin Calcium383$4,093
Metoprolol Succinate235$3,684
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,497
Gabapentin184$3,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$93$122,57374 claims
Boehringer IngelheimJardiance$74$71,69556 claims
Lilly USA, LLCMounjaro, Trulicity$96$65,83344 claims
MerckJanuvia, Janumet$20$52,99237 claims
AstraZenecaFarxiga$192$16,98616 claims
AbbVieSynthroid$52$2,51630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Howard Beach

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →